US Bancorp DE lowered its stake in shares of The Clorox Company (NYSE:CLX) by 1.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,734 shares of the company’s stock after selling 1,894 shares during the quarter. US Bancorp DE owned about 0.13% of The Clorox worth $22,726,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Centaurus Financial Inc. acquired a new position in shares of The Clorox during the first quarter valued at about $106,000. Prime Capital Investment Advisors LLC acquired a new position in shares of The Clorox during the fourth quarter valued at about $123,000. Tiemann Investment Advisors LLC acquired a new position in shares of The Clorox during the fourth quarter valued at about $200,000. Nicholas Hoffman & Company LLC. acquired a new position in shares of The Clorox during the fourth quarter valued at about $201,000. Finally, Lourd Capital LLC acquired a new position in shares of The Clorox during the fourth quarter valued at about $210,000. Hedge funds and other institutional investors own 76.39% of the company’s stock.
Get The Clorox alerts:The Clorox opened at $118.33 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.93 and a current ratio of 1.18. The Clorox Company has a 12 month low of $117.44 and a 12 month high of $118.56. The company has a market capitalization of $15.33 billion, a price-to-earnings ratio of 22.12, a P/E/G ratio of 2.65 and a beta of 0.37.
The Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, May 2nd. The company reported $1.37 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.06. The Clorox had a return on equity of 107.93% and a net margin of 13.27%. The business had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.51 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. sell-side analysts expect that The Clorox Company will post 5.73 earnings per share for the current year.
Several brokerages recently weighed in on CLX. Barclays reiterated a “hold” rating and issued a $135.00 price target on shares of The Clorox in a report on Friday, March 16th. Bank of America cut their price target on shares of The Clorox from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Thursday, May 3rd. BMO Capital Markets set a $147.00 price target on shares of The Clorox and gave the stock a “buy” rating in a report on Monday, February 5th. Wells Fargo cut their price target on shares of The Clorox from $140.00 to $130.00 and set a “market perform” rating on the stock in a report on Thursday, April 19th. Finally, Zacks Investment Research downgraded shares of The Clorox from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. The Clorox presently has a consensus rating of “Hold” and an average target price of $130.98.
About The Clorox
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighters and color boosters; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning and disinfecting products under the Clorox, Dispatch, Aplicare, HealthLink, and Clorox Healthcare brands.
No comments:
Post a Comment